Dutch biopharmaceutical SME specializing in continuous bioprocessing, bioreactor control, and downstream manufacturing of drug proteins and biologics.
Byondis is a Dutch biopharmaceutical SME based in Nijmegen that develops and manufactures targeted therapies, with deep expertise in antibody-based drugs and the bioprocessing technology needed to produce them at clinical and commercial scale. Their H2020 footprint centers on the industrial side of biologics: bioreactor cultivation, real-time process analytics, continuous downstream purification, and regulatory-ready manufacturing of drug proteins. They bring an industry perspective to academic consortia — training young researchers and helping translate lab-scale bioprocess science into robust production platforms.
iConsensus (2018-2022) focused on integrated control and sensing for high-throughput biopharmaceutical cultivation, including at-line and on-line analysis of drug proteins.
CODOBIO (2019-2023) addressed continuous downstream processing of bioproducts, with emphasis on control engineering and regulatory pathways.
NANOMED (2016-2019) contributed to an integrative approach to nanomedicine through an MSCA-ITN training network.
Acted as industry partner in two MSCA-ITN networks (NANOMED, CODOBIO) hosting and co-supervising PhD candidates.
Their earliest H2020 engagement (NANOMED, 2016) was broad and academic — an MSCA training network on nanomedicine with no strong technology signature in the keywords. From 2018 onwards the profile sharpens decisively toward the engineering of biologics production: bioreactor cultivation, on-line and at-line analytics, continuous manufacturing, and regulatory-compliant downstream processing. The shift is from general drug-science training to a concrete industrial focus on making biopharmaceuticals faster, cleaner, and continuously.
Byondis is moving deeper into continuous, instrumented bioprocessing — a strong fit for anyone building consortia around biologics manufacturing, process analytical technology, or GMP-ready bioproduction.
Byondis consistently joins as an industry partner rather than coordinating — it has never led an H2020 project but has been a reliable contributor across three consortia spanning 50 partners in 13 countries. They prefer large multi-country networks, especially MSCA training networks, where their role is to provide industrial context and hosting placements. Partnering with them means tapping into a small, focused biopharma company willing to engage with academia rather than drive the agenda.
They have collaborated with 50 unique partners across 13 European countries, reflecting participation in sizeable MSCA and RIA consortia rather than bilateral work. The footprint is clearly European, with no signs of a narrow regional focus.
Most small Dutch biotechs stay on the therapeutic-discovery side; Byondis stands out by actively engaging in the manufacturing-science layer — bioreactor control, continuous downstream processing, and process analytics. They offer something rare: an SME with real biopharmaceutical production know-how that is still small enough to co-supervise PhDs and engage with academic consortia. For partners in biologics, PAT, or continuous processing, they are a credible industrial anchor without the bureaucracy of a pharma major.
